FIELD: pharmaceutics.
SUBSTANCE: invention relates to pharmaceutical combination for cancer treatment containing therapeutically effective amount of formula (I) compound and an additional therapeutically active agent selected from a group consisting of antibody against PD-1, antibody against PD-L1 and olaparib, wherein cancer is selected from mammary gland cancer, colon cancer, and skin cancer, as well as method for treatment and relief of a cancer in the subject, including injection of therapeutically effective amount of pharmaceutical combination to the subject in need of it.
EFFECT: technical result is creation of combined therapy for cancer treatment.
29 cl, 22 dwg, 5 tbl, 5 ex
| Title | Year | Author | Number |
|---|---|---|---|
| COMBINATION THERAPY WITH TETRACYCLIC QUINOLONE ANALOGUES FOR TREATMENT OF CANCER | 2016 |
|
RU2786570C2 |
| METHOD OF TREATMENT BY APPLICATION OF COMBINED THERAPY | 2010 |
|
RU2543348C2 |
| MEK INHIBITORS AND THEIR THERAPEUTIC USE | 2021 |
|
RU2812929C1 |
| QUINOLINE DERIVATIVES FOR USE IN TREATMENT OR PREVENTION OF CANCER | 2019 |
|
RU2811417C2 |
| BIOMARKERS AND APPLICATIONS IN TREATING VIRAL INFECTIONS, INFLAMMATIONS OR CANCER | 2019 |
|
RU2820481C2 |
| PHARMACEUTICAL COMBINATIONS FOR TREATING A MALIGNANT TUMOR | 2017 |
|
RU2726367C2 |
| COMBINED THERAPY FOR CANCER TREATMENT | 2013 |
|
RU2699546C2 |
| CONFORMATIONALLY RESTRICTED PI3K AND MTOR INHIBITORS | 2014 |
|
RU2669696C2 |
| PURINONE COMPOUNDS AS KINASE INHIBITORS | 2013 |
|
RU2655388C2 |
| N-SUBSTITUTED DIOXOCYCLOBUTENYLAMINO-3-HYDROXYPICOLINAMIDES SUITABLE AS CCR6 INHIBITORS | 2019 |
|
RU2784831C2 |
